Real World Evidence and Market Access

Evidence Driven Patient Access

Real World Evidence (RWE) and Market Access (MA) are increasingly crucial for life sciences companies to ensure patient access and commercial success. Both domains require technical expertise along with strategic insights for informed healthcare decisions and optimal outcomes.

RWE is being widely used to gain an understanding of disease epidemiology, patient journey, real-world use and effectiveness of treatment options, unmet patient needs and the value that products offer in sub-populations. Sciformix offers end-to-end RWE and late phase services such as study planning, protocol development, clinical study management and reporting.

Market Access requirements span from early product stages (e.g., providing input into R&D, business planning, licensing opportunities, policy landscape) to later stages (e.g., formulary access, tendering and pricing). Market Access is our focus practice area with services spanning across the product lifecycle.

Our collaborative approach, while being cognizant of client needs, also ensures a seamless partnership that delivers scientific and operational excellence. Sciformix offers end-to-end RWE and MA services as detailed below.

Real World Studies: One stop solution for patient registries, observational studies covering prospective, retrospective, comparative & exploratory study designs, chart reviews, electronic health record (EHR) studies, surveys, claims data analysis

Global Market Access and Pricing: Market access landscape analysis, payer archetypes & requirement assessment, global value dossier (GVD) development, local go-to market access strategy, pricing & reimbursement research, payer & key opinion leader (KOL) mapping, value proposition development, health technology assessment (HTA) review & monitoring, international reference pricing & launch planning, risk sharing agreements & patient access schemes

Health Economics and Outcomes Research (HEOR): Pharmacoeconomic modeling, cost effectiveness analysis, budget impact analysis, disease & epidemiological modelling, systematic literature reviews, data synthesis, meta-analysis, willingness to pay & patient preference studies, comparative effectiveness research (CER), patient reported outcomes (PROs) research, endpoint review & analysis

Market Access Technology Solutions: Development of technology solutions for market access needs i.e. payer value communications tools, formulary/budget holder interaction tools & training for key account managers (KAMs), iPad apps for GVD, global payer network & ad-board platform, customized regulatory-HTA integrated database services